vs
渤健（BIIB）与Cellectis S.A.（CLLS）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Cellectis S.A.的239.8倍（$2.3B vs $9.5M）。渤健净利率更高（-2.1% vs -265.9%，领先263.7%）。Cellectis S.A.同比增速更快（375.0% vs -7.1%）。渤健自由现金流更多（$468.0M vs $27.6M）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
BIIB vs CLLS — 直观对比
营收规模更大
BIIB
是对方的239.8倍
$9.5M
营收增速更快
CLLS
高出382.1%
-7.1%
净利率更高
BIIB
高出263.7%
-265.9%
自由现金流更多
BIIB
多$440.4M
$27.6M
损益表 — Q4 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $9.5M |
| 净利润 | $-48.9M | $-25.3M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | -181.1% |
| 净利率 | -2.1% | -265.9% |
| 营收同比 | -7.1% | 375.0% |
| 净利润同比 | -118.3% | -51.9% |
| 每股收益（稀释后） | $-0.35 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBCLLS
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | $9.5M | ||
| Q1 24 | $2.3B | — |
净利润BIIBCLLS
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | — | ||
| Q2 25 | $634.8M | — | ||
| Q1 25 | $240.5M | — | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $583.6M | $-25.3M | ||
| Q1 24 | $393.4M | — |
毛利率BIIBCLLS
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBCLLS
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | -181.1% | ||
| Q1 24 | 20.3% | — |
净利率BIIBCLLS
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 24.0% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 23.7% | -265.9% | ||
| Q1 24 | 17.2% | — |
每股收益（稀释后）BIIBCLLS
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | $-0.28 | ||
| Q1 24 | $2.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $149.0M |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $148.6M |
| 总资产 | $29.4B | $407.1M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBCLLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $149.0M | ||
| Q1 24 | — | — |
总债务BIIBCLLS
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBCLLS
| Q4 25 | $18.3B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $17.6B | — | ||
| Q1 25 | $17.0B | — | ||
| Q4 24 | $16.7B | — | ||
| Q3 24 | $16.4B | — | ||
| Q2 24 | $15.9B | $148.6M | ||
| Q1 24 | $15.2B | — |
总资产BIIBCLLS
| Q4 25 | $29.4B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.3B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $28.0B | — | ||
| Q3 24 | $28.3B | — | ||
| Q2 24 | $26.8B | $407.1M | ||
| Q1 24 | $26.6B | — |
负债/权益比BIIBCLLS
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $27.6M |
| 自由现金流率自由现金流/营收 | 20.5% | 290.5% |
| 资本支出强度资本支出/营收 | 1.9% | 13.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBCLLS
| Q4 25 | $511.9M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $160.9M | — | ||
| Q1 25 | $259.3M | — | ||
| Q4 24 | $760.9M | — | ||
| Q3 24 | $935.6M | — | ||
| Q2 24 | $625.8M | $28.9M | ||
| Q1 24 | $553.2M | — |
自由现金流BIIBCLLS
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | $27.6M | ||
| Q1 24 | $507.3M | — |
自由现金流率BIIBCLLS
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | 290.5% | ||
| Q1 24 | 22.1% | — |
资本支出强度BIIBCLLS
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | 13.2% | ||
| Q1 24 | 2.0% | — |
现金转化率BIIBCLLS
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
CLLS
暂无分部数据
